Importantly, JNK signaling appears to be critical in these tumors, as shown by the increased tumor burden observed in a transgenic model of JNK activation and the heightened sensitivity of c-Jun–null lung tumor cells to JNK inhibitors. This evidence concerns the gene MAPK8 and neoplasm.